Compare Ferrari NV (RACE) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs GeneDx Holdings Corp — how do they compare? Ferrari NV trades at $389.91 (market cap $67.35B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Ferrari NV is far larger — about 33.3× GeneDx Holdings Corp's market cap, and Ferrari NV pays a 1.09% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ferrari NV for 126 Days and GeneDx Holdings Corp for 19 Days on average.
| RACE | WGS | |
|---|---|---|
Market Cap | $67.35B | $2.02B |
Volume | 390,618 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $436.54 | $167.51 |
52-Week Low | $314.63 | $34.51 |
Typical Hold Time | 126 Days | 19 Days |
Enterprise Value | $69.22B | $2.05B |
Dividend Yield | 1.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $388.28, up 0.49% today, with a bearish technical signal but strong fundamentals. The stock has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $7.15B in 2025, with a net income margin of 22.25% and robust ROE of 45.45%. The company is executing a share buyback program and recently announced a partnership with Rakuten effective January 2027.
The outlook is positive given strong profitability, consistent earnings beats, and analyst consensus favoring a buy rating with a $462.75 price target. Risks include high valuation multiples (P/E 37.19) and exposure to economic cycles affecting luxury demand. Institutional buying and buyback support provide downside cushion, but investors should monitor execution on future growth initiatives.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
